Skip to content

16-186 - Clinical Trial to Evaluate the Effectiveness and safety of Immunotherapy in Combination with Chemotherapy and Radiation (Chemoradiation) for the Treatment of Advanced Cervical Cancer

Status: open

A randomized Phase II study of chemoradiation and pembrolizumab for locally advanced cervical cancer

Treatment for Cervical Cancer

Contact Us


The purpose of this study is to evaluate the safety and effectiveness of immunotherapy in combination with chemotherapy and radiation (chemoradiation) for the treatment of advanced cervical cancer. Pembrolizumab, a type of immunotherapy called a checkpoint inhibitor, will be administered after or during chemoradiation. IRB Number 16-186


This trial is sponsored by Merck.

Providers Associated With This Trial

Principle Investigator

    Sub Investigators

      This link will open in a new tab or window.